The number that stops the scroll
Weight loss gets the headlines for retatrutide, the once-weekly triple agonist that Eli Lilly is developing. But a new post hoc analysis of two phase 2 trials, published in Diabetes, Obesity & Metabolism by Ruotolo and colleagues, looks at what happened to the blood. The most striking result is a drop of up to 84.4% in large triglyceride-rich lipoprotein particles in adults with type 2 diabetes (T2D), and up to 76.6% in adults without it.
Before anyone gets excited, three caveats. This is a post hoc analysis. Retatrutide is not approved anywhere. And it is a prescription-class investigational drug, not a supplement. With that said, the data are worth a close look.
What the researchers actually did
The team pooled biomarker data from two randomized, double-blind, placebo-controlled phase 2 trials (ClinicalTrials.gov NCT04881760 and NCT04867785):
- Study 1: Adults with obesity/overweight and T2D received once-weekly retatrutide (0.5, 4, 8 or 12 mg), dulaglutide 1.5 mg, or placebo for 36 weeks. Mean BMI was 35.4 kg/m².
- Study 2: Adults with clinical obesity but no T2D received once-weekly retatrutide (1, 4, 8 or 12 mg) or placebo for 48 weeks. Mean BMI was 37.4 kg/m².
Fasting blood samples were taken at baseline and during treatment. The panel covered lipids, apolipoproteins, lipoprotein particle subclasses and inflammatory markers. The authors used mixed models for repeated measures to estimate placebo-adjusted change from baseline. Significance required a false discovery rate-adjusted p < 0.05.
The lipid findings: ApoB, LDL particles and triglyceride-rich lipoproteins
In both studies, retatrutide was associated with significant reductions in markers of atherogenic particle burden. The abstract reports the largest placebo-adjusted changes as "up to" values (Study 1 / Study 2):
| Marker | Study 1 (T2D) | Study 2 (no T2D) |
|---|---|---|
| Non-HDL cholesterol | up to −21.0% | up to −26.9% |
| Apolipoprotein B | −21.4% | −24.2% |
| Total triglyceride-rich lipoprotein (TRL) particles | −22.5% | −33.7% |
| Large TRL particles | −84.4% | −76.6% |
| TRL cholesterol | −29.4% | −38.6% |
| Total LDL particles | −19.7% | −23.5% |
| Small LDL particles | −32.6% | −32.3% |
ApoB matters because each atherogenic particle, whether LDL, VLDL remnant or others, carries one ApoB molecule. A fall in ApoB therefore suggests fewer artery-penetrating particles, not just less cholesterol per particle. The drop in small LDL particles and large TRLs points to a shift in the whole particle profile, beyond the standard LDL-C number.
The inflammation signal: hsCRP and IL-6
In Study 2, the trial without T2D, retatrutide was associated with a 54.8% reduction in high-sensitivity C-reactive protein and a 29.6% reduction in interleukin-6. These changes were not significant in Study 1.
The abstract does not explain the difference. The studies differed in population, duration (36 vs 48 weeks) and dose ranges, so it would be a mistake to read much into the gap without the full paper.
What about Lp(a) and the dose-by-dose breakdown?
If you came here for Lp(a) numbers, the abstract does not report any, so no claim about retatrutide and Lp(a) can be drawn from it. The abstract also gives only the maximum "up to" changes. It does not tie each figure to a specific dose, so a dose-response claim would go beyond what the abstract shows. For per-dose figures, including any lipoprotein(a) results, readers should consult the full text (DOI: 10.1111/dom.71200).
Why this matters
Obesity and T2D drive cardiovascular risk partly through atherogenic dyslipidemia: more triglyceride-rich remnants, more small LDL particles and more inflammation. The authors conclude that retatrutide was associated with reductions in atherogenic lipoproteins and inflammatory biomarkers linked to cardiovascular disease risk. That is encouraging, but biomarkers are not outcomes. These trials were not designed to show fewer heart attacks or strokes, and the analysis cannot say whether the changes translate into fewer events.
The lipid changes may also partly reflect weight loss rather than a separate drug effect. This analysis cannot separate the two.
Practical takeaways
Dose and timing. There is no dose you can follow. Retatrutide is investigational. In these trials it was given once weekly by the study protocol, at 0.5–12 mg in Study 1 and 1–12 mg in Study 2, for 36 or 48 weeks. Those are trial regimens, not recommendations.
Who the data apply to. The participants were adults with obesity or overweight, with or without T2D. Their mean BMI was in the mid-to-high 30s, and they were monitored in clinical trials.
Who should skip it. Anyone hoping to get retatrutide outside a regulated trial should skip it. That includes buying gray-market or "research chemical" vials online. The product is unapproved, and the purity, dose and sterility of such products cannot be verified. This is not a supplement and should not be treated like one. People with cardiovascular risk should discuss approved options and proven lipid management with a clinician.
What to watch. Larger phase 3 trials and cardiovascular outcome data will show whether these biomarker shifts hold up and matter clinically.
The bottom line
In two phase 2 trials, retatrutide was associated with large placebo-adjusted reductions in ApoB, non-HDL cholesterol, LDL particles and triglyceride-rich lipoproteins. It was also associated with lower hsCRP and IL-6 in the non-diabetic trial. The numbers are impressive, but they come from a post hoc analysis of an unapproved drug and show biomarker changes, not proven clinical benefit.
Source: Ruotolo et al., "Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes," Diabetes, Obesity & Metabolism. PubMed: 42608321. DOI: 10.1111/dom.71200.
